Boehringer Says Its App Reduces Negative Schizophrenia Symptoms

Boehringer Ingelheim GmbH and Click Therapeutics Inc. said their digital therapy app reduced symptoms of schizophrenia in a late-stage study, a potential breakthrough for sufferers with few treatment options.

Patients in a 16-week study who used the smartphone app in conjunction with traditional psychotherapy experienced fewer symptoms such as lack of motivation and reduced speech, the German pharmaceutical company said in a joint statement Thursday with Click, a US-based health software developer.

The complications, known as negative symptoms since they depress emotions, affect about 60% of the estimated 24 million people with schizophrenia globally, a study cited by the ...